Scott Tarriff compensation by year
EAGLE PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Salary | $769,410 | $769,410 | $822,093 | $815,914 | $848,940 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $5,681,970 | $2,599,120 | $3,485,757 | $4,293,836 | $9,011,197 |
| Option awards | $4,199,835 | $2,955,330 | $4,584,223 | $0 | $0 |
| Non-equity incentive | $654,000 | $1,538,800 | $554,750 | $1,338,700 | $636,705 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $19,241 | $21,017 | $22,610 | $23,071 | $23,735 |
| Total | $11,324,456 | $7,883,677 | $9,469,433 | $6,471,521 | $10,520,577 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: EAGLE PHARMACEUTICALS, INC. DEF 14A filed May 1, 2023, accession 0001104659-23-054338, and prior-year filings. Open the filing on EDGAR.
How this page was built: the EAGLE PHARMACEUTICALS, INC. filed document, accession 0001104659-23-054338. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 60,400 | $3,075,568 | — |
| PSU | 104,500 | $3,054,535 | — |
| PSU | 25,900 | $1,318,828 | — |
| RSU | 34,800 | $1,017,204 | — |
| RSU | 29,150 | $852,055 | — |
| RSU | 15,325 | $447,950 | — |
| Option | 39,460 | — | $59.79 |
| Option | 2,858 | — | $42.40 |
Per the Outstanding Equity Awards at Fiscal Year-End table in EAGLE PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
15 Form 4 lines since the FY2022 proxy (filed May 1, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-02-28 | Tax withholding | — | 2,119 | $6.27 | 460,621 |
| 2024-02-27 | Tax withholding | — | 3,154 | $6.44 | 462,740 |
| 2024-02-27 | Grant or award | — | 12,950 | — | 465,894 |
| 2024-01-05 | Tax withholding | — | 4,322 | $5.13 | 541,125 |
| 2023-11-02 | Sale | 10b5-1 | 10,694 | $13.87 | 545,447 |
| 2023-11-01 | Sale | 10b5-1 | 10,925 | $13.82 | 556,141 |
| 2023-10-03 | Sale | 10b5-1 | 710 | $15.11 | 567,066 |
| 2023-10-03 | Sale | 10b5-1 | 10,024 | $14.41 | 567,776 |
The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments EAGLE PHARMACEUTICALS discloses, by trigger · FY2022| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $2,122,350 | $7,825,651 | $34,163 | $9,982,164 |
| Resignation for good reason, no change in control | $2,122,350 | $7,825,651 | $34,163 | $9,982,164 |
| Change in control and resignation for good reason | $3,395,760 | $7,825,651 | $45,550 | $11,266,961 |
| Disability | $0 | $7,825,651 | $0 | $7,825,651 |
| Change in control, no termination | $0 | $7,825,651 | $0 | $7,825,651 |
| Change in control and involuntary termination | $3,395,760 | $7,825,651 | $45,550 | $11,266,961 |
| Death | $0 | $7,825,651 | $0 | $7,825,651 |
Per the Potential Payments Upon Termination or Change in Control table in EAGLE PHARMACEUTICALS, INC.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.
EAGLE PHARMACEUTICALS’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Scott Tarriff · this page | President, Chief Executive Officer, Director | $10,520,577 |
| Michael Moran | Former Chief Commercial Officer | $2,608,325 |
| Brian Cahill | Chief Financial Officer | $2,493,347 |
Board service
EAGLE PHARMACEUTICALS board · FY2021–FY2022How this board is paid
Company policy: EAGLE PHARMACEUTICALS pays directors a $65,000 cash retainer. As stated in EAGLE PHARMACEUTICALS's FY2022 proxy.
Committees
Strategic Clinical Development
The full EAGLE PHARMACEUTICALS compensation record
free company briefThis page is one person within EAGLE PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the EAGLE PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are EAGLE PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.